This popular brochure has been updated to reflect the latest advances in detection, prevention, and treatment (released in November 2011). It guides readers through the latest information on age-related macular degeneration symptoms and risk factors, while offering ways to help reduce risk. The widely used Amsler Grid can still be found on the back cover.

On October 24th, Alliance President & CEO Daniel Perry presented remarks at a public meeting on the fifth reauthorization of the Prescription Drug User Fee Act (PDUFA). PDUFA IV, currently set to expire in September of 2012, authorizes the Food and Drug Administration (FDA) to collect user fees from companies wishing to submit their products for agency review. The intention is that the fees would be used to provide an additional revenue stream for FDA to hire more staff, improve systems, and establish a better managed drug review process to speed up the delivery of needed therapies to the public. The PDUFA reauthorization process has historically been conducted through negotiations between the Agency and regulated industries, however the current round of negotiations allowed for patient groups to engage in monthly consultations with FDA representatives to enable all stakeholders to have an early voice in shaping the PDUFA V agreement.

This tip sheet tells you what to expect during a comprehensive eye exam--the key to detecting glaucoma and preventing its serious consequences.

A Declaration from the Glaucoma Working Group to Take Action to Know your Eyes

Today, more than 40 million Americans are age 65 or older.  By 2050, it is estimated that figure will rise to 88.5 million.  Our nation is aging rapidly, and this demographic shift likely means longer hospital stays, more doctor visits, and greater healthcare expenditures for more and more Americans.  If you're a Baby Boomer and looking ahead to your silver years, you already have plenty to think about: retirement, the economy, elderly parents, and young adult children.  It's hard to find time to focus on your health--especially if you feel healthy!

The most common type of arrhythmia—or abnormal heart rhythm—atrial fibrillation (AFib) is a disorder of the heart’s electrical system that affects an estimated 2.3 to 5.6 million people in the US. During AFib episodes the heart’s upper chambers (the atria) beat irregularly and out of sync with the heart’s lower chambers (the ventricles). In some people these episodes come and go. In others they are chronic and occur regularly. In both cases, the arrhythmia itself isn’t generally serious; however, abnormal blood flow and strain to the heart can lead to serious medical conditions.

Download to learn more about what it means to have AFib, risk factors, treatment options, and making the right treatment decision for you.